Palvella Therapeutics (PVLA) EBITDA Margin (2016 - 2024)
Historic EBITDA Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 1859.67%.
- Palvella Therapeutics' EBITDA Margin fell 10625000.0% to 1859.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 13617.97%, marking a year-over-year increase of 135762200.0%. This contributed to the annual value of 4053.72% for FY2024, which is 40118700.0% up from last year.
- Per Palvella Therapeutics' latest filing, its EBITDA Margin stood at 1859.67% for Q4 2024, which was down 10625000.0% from 5150.94% recorded in Q1 2024.
- In the past 5 years, Palvella Therapeutics' EBITDA Margin ranged from a high of 2922.17% in Q4 2023 and a low of 5150.94% during Q1 2024
- Its 5-year average for EBITDA Margin is 223.63%, with a median of 131.14% in 2021.
- As far as peak fluctuations go, Palvella Therapeutics' EBITDA Margin surged by 30740700bps in 2023, and later plummeted by -44865200bps in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' EBITDA Margin stood at 741.24% in 2020, then soared by 85bps to 110.38% in 2021, then tumbled by -38bps to 151.9% in 2022, then skyrocketed by 2024bps to 2922.17% in 2023, then tumbled by -36bps to 1859.67% in 2024.
- Its last three reported values are 1859.67% in Q4 2024, 5150.94% for Q1 2024, and 2922.17% during Q4 2023.